Clinical Trial Update: Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST [Phase 3]

View source ↗

Summary

A Phase 3 trial of bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension was terminated, with results posted in May 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease-associated Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2023-05-19